SCHEMBL1471293

SCHEMBL1471293

O=C1C=C(c2ccccc2)C(=O)N1c1cc(Br)cc(Br)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
MAPT P10636 4/20 0.49
NPSR1 Q6W5P4 3/20 0.49
GAA P10253 2/20 0.49
CCR6 P51684 2/20 0.49
HPGD P15428 2/20 0.49
ALOX12 P18054 2/20 0.49
CACNA1B Q00975 2/20 0.49
APBA1 Q02410 2/20 0.49
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
HSP90AA1 P07900 2/20 0.40
HCRTR1 O43613 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
MGLL Q99685 4/20 0.39
FAAH O00519 2/20 0.38
PKM P14618 1/20 0.38
ATM Q13315 1/20 0.38
RGS4 P49798 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471735 0.87 MGLL (0.56) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL1471161 0.85 MAPT (0.50) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL303331 0.84 ALDH1A1 (0.51) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL1471709 0.83 ALDH1A1 (0.47) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL1473649 0.78 ALDH1A1 (0.41) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL934144 0.78 MGLL (0.53) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL1471763 0.78 ALDH1A1 (0.43) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL1473687 0.77 MGLL (0.47) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL1471657 0.77 MAPT (0.54) ALDH1A1MAPTNPSR1GAACCR6
SCHEMBL1471189 0.77 ALDH1A1 (0.57) ALDH1A1MAPTNPSR1GAACCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 ALDH1A1 800/4885MAPT 1947/4885NPSR1 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.